PATENTS


**GRANTS**

2011 Health Professions Division’s Grant, NSU ($5,000)
Title: Quantification of Xylitol released from tooth wipes in an in vitro experiment.

2009 President’s Faculty Research and Development Grant ($10,000)
Title: Novel approach for the drug delivery of epinephrine for anaphylaxis

2008 Health Professions Division’s Grant, NSU ($5,000)
Title: Sublingual epinephrine tablets for the non-invasive emergency treatment of anaphylaxis

2007 Natural Sciences and Engineering Research Council (NSERC) Industrial Grant ($30,000/year for 2 years)
Title: Ophthalmic drug formulation and delivery

**PUBLICATIONS**

A) Papers:


B) Peer-Reviewed Abstracts & Posters Presentation:


5. **Rawas-Qalaji MM**, Simons ER, Simons KJ. Pre-Loaded Epinephrine Syringes Stored Under Light in Dry or Humid Conditions at 38 °C for 5 Days are Stable for Emergency Treatment of Anaphylaxis. *AAPSJ* 2004; 6(S1): T3115 - Baltimore, MD (Nov 7-10)

Evidence and Provincial Reimbursement Status. *AAPSJ* 2004; 6(S1): T2372 - Baltimore, MD (Nov 7-10)


11. **Rawas-Qalaji MM**, Simons ER, Simons KJ. Epinephrine for the Treatment of Anaphylaxis: Do all Sublingual Epinephrine Tablet Formulations with Similar In Vitro Characteristics have the Same Bioavailability? *AAPSJ* 2006; 8(S2): M1369 - San Antonio, TX (Oct 29-Nov 2)


**PRESENTATIONS**

1. **Rawas-Qalaji MM**. The Role of b-Blockers in Heart Failure. Roche Symposium on Advances in the Management of Cardiovascular Diseases, Singapore, 1999

2. **Rawas-Qalaji MM**. Epinephrine for the Treatment of Anaphylaxis: Sublingual Epinephrine Tablet Versus EpiPen®. Podium presentation during Allergy session in the American Academy of Allergy Asthma and Immunology Annual Meeting in Miami Beach, Florida (Mar 3-7, 2006)

3. **Rawas-Qalaji MM**. A Novel Approach for the Emergency Treatment of Anaphylaxis. School of Pharmacy-University of Waterloo, Ontario, Canada, June 2008
4. **Rawas-Qalaji MM.** A Novel Approach for the treatment of Anaphylaxis. Ebla Private University, Aleppo, Syria, June 2010

5. **Rawas-Qalaji MM.** A Novel Approach for the treatment of Anaphylaxis. Asia Pharmaceutical Industries, Aleppo, Syria, July 2010


7. **Rawas-Qalaji MM.** Fabrication of Epinephrine Nanoparticles: Success and Failures. Graduate Seminar, College of Pharmacy-Nova Southeastern University, Florida, November 2011
